Allplex MDRO assay expands AMR testing capabilities in Europe
Multiplex PCR test supports rapid detection of multidrug‑resistant organisms in hospital settings
29 May 2026Product news
Seegene’s Allplex™ MDRO Assay is designed to support detection of multidrug-resistant organisms (MDROs)
Seoul-based molecular diagnostics company Seegene has launched its new antimicrobial resistance (AMR) testing product, Allplex™ MDRO Assay, in Europe. The assay, which is CE marked under the EU In Vitro Diagnostic Regulation (IVDR), is designed to support the detection of multidrug-resistant organisms (MDROs) associated with healthcare-associated infections (HAIs) in hospital settings.
By enabling rapid first-line PCR screening and simultaneous detection of multiple resistance genes, the assay aims to support timely infection prevention and control responses and broaden Seegene’s non-respiratory AMR testing portfolio.
Expanding MDRO testing in hospital settings
The Allplex™ MDRO Assay is designed to identify key multidrug-resistant pathogens and associated resistance genes in a single run. This enables rapid, simultaneous detection across a broader range of MDRO targets in hospital environments where healthcare-associated infections are a growing concern.
By supporting first-line screening before culture-based results are available, the assay can help infection prevention and control (IPC) teams respond more quickly to potential outbreaks. This approach is intended to complement conventional culture-based workflows and provide laboratories with additional tools to manage high-risk MDROs.
Addressing the growing burden of antimicrobial resistance
As antimicrobial resistance continues to rise globally, the burden of healthcare-associated infections is increasing, driving demand for faster and more comprehensive diagnostic approaches. Public health agencies, including the U.S. Centers for Disease Control and Prevention (CDC), have highlighted the need for strengthened infection surveillance and control capabilities in healthcare settings.
Seegene’s launch of the Allplex™ MDRO Assay reflects its strategy to expand AMR testing capabilities in line with evolving infectious disease trends and the growing need for rapid, accurate detection of multidrug-resistant organisms.
Complementing Seegene’s existing AMR portfolio
The Allplex™ MDRO Assay complements Seegene’s existing Allplex™ Entero-DR Assay, enabling a combined testing approach that covers both antimicrobial-resistant enteric bacteria and additional high-risk MDRO targets. This broader coverage is designed to support more comprehensive infection-control efforts against antimicrobial-resistant organisms in hospitals.
By integrating both assays into laboratory workflows, healthcare facilities can strengthen their overall AMR testing strategies and improve their ability to detect and monitor a wide range of resistant pathogens.
Supporting rapid reporting and laboratory efficiency
The Allplex™ MDRO Assay enables simultaneous detection of multiple resistance genes and can support same-day reporting, depending on laboratory workflow. This rapid turnaround can provide timely information to guide infection-control responses and inform clinical decision-making.
The assay is also intended to complement conventional culture-based workflows and may help support more efficient laboratory operations in appropriate clinical settings by streamlining first-line screening for MDROs.
Commitment to real-world clinical implementation
“This launch represents more than just the addition of a new product. It marks an important step in expanding our diagnostic portfolio to support broader infection control efforts in hospital settings,” said Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene. “We will continue to develop diagnostic solutions that can be effectively implemented in real-world clinical environments.”
Seegene plans to further strengthen its diagnostic capabilities for healthcare-associated infections and advance its strategy in line with growing demand for enhanced infection surveillance and control. Product availability may vary by country and is subject to local regulatory requirements.
Future plans for MRSA detection
As part of its broader AMR testing portfolio expansion strategy, Seegene is also developing the Allplex MRSA Assay for detection of methicillin-resistant Staphylococcus aureus (MRSA). This assay is targeted for launch next year and is intended to further support hospitals and laboratories in managing high-risk, multidrug-resistant pathogens.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
What is Seegene’s Allplex™ MDRO Assay and how does it support detection of multidrug-resistant organisms (MDROs) in hospital settings?
Seegene’s Allplex™ MDRO Assay is a CE-marked in vitro diagnostic test, launched in Europe under the EU In Vitro Diagnostic Regulation (IVDR). Developed by the Seoul-based molecular diagnostics company Seegene, the assay is designed to support detection of multidrug-resistant organisms (MDROs) associated with healthcare-associated infections (HAIs) in hospital environments. It enables rapid first-line PCR screening and simultaneous detection of multiple resistance genes in a single run, allowing laboratories and infection prevention and control (IPC) teams to identify key multidrug-resistant pathogens more quickly.
By providing same-day reporting depending on laboratory workflow, the assay supports timely infection-control responses, complements conventional culture-based workflows, and helps hospitals manage high-risk MDROs more efficiently.
How does the Allplex™ MDRO Assay expand Seegene’s antimicrobial resistance (AMR) testing portfolio and complement the Allplex™ Entero-DR Assay?
The Allplex™ MDRO Assay is a central component of Seegene’s strategy to expand its antimicrobial resistance (AMR) testing capabilities in line with evolving infectious disease trends and the growing burden of healthcare-associated infections. It complements the existing Allplex™ Entero-DR Assay by enabling a combined testing approach that covers both antimicrobial-resistant enteric bacteria and additional high-risk MDRO targets.
This broader coverage is designed to support more comprehensive infection-control efforts against antimicrobial-resistant organisms in hospitals. By integrating both assays into laboratory workflows, healthcare facilities can strengthen their overall AMR testing strategies, improve their ability to detect and monitor a wide range of resistant pathogens, and streamline first-line screening while maintaining conventional culture-based methods.
What future plans does Seegene have for MRSA detection and how do they relate to its broader infection surveillance and control strategy?
As part of its broader AMR testing portfolio expansion strategy, Seegene is developing the Allplex MRSA Assay for detection of methicillin-resistant Staphylococcus aureus (MRSA), a high-risk multidrug-resistant pathogen commonly associated with healthcare settings. This MRSA assay is targeted for launch next year and is intended to further support hospitals and laboratories in managing multidrug-resistant organisms.
Together with the Allplex™ MDRO Assay and Allplex™ Entero-DR Assay, the planned MRSA test reflects Seegene’s commitment to strengthening diagnostic capabilities for healthcare-associated infections, enhancing infection surveillance and control, and delivering diagnostic solutions that can be effectively implemented in real-world clinical environments. Product availability for these assays may vary by country and is subject to local regulatory requirements.